Miltefosine, an oral agent, for the treatment of indian visceral leishmaniasis

New England Journal of Medicine

Volumn 341, Issue 24, 1999, Pages 1795-1800

  Jha, T K ^a   Sundar, Shyam ^b   Thakur, C P ^c   Bachmann, Peter ^d   Karbwang, Juntra ^e   Fischer, Christina ^d   Voss, Andreas ^d   Berman, Jonathan ^e  

^a Kala azar Research Center   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c Balaji Utthan Sansthan   (India)

^d ASTA MEDICA AG   (Germany)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; MILTEFOSINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; ASPARTATE AMINOTRANSFERASES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; RECURRENCE; TREATMENT OUTCOME;

EID: 0033540005     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199912093412403     Document Type: Article

References (22)

1. Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol 1996;14:417-23.
2. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999;28:42-8.
3. Berman J. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999;28:49-51.
4. Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 1997;126:232-6.
5. Wali JP, Aggarwal P, Gupta U, Saluja S, Singh S. Ketoconazole in treatment of visceral leishmaniasis. Lancet 1990;336:810-1.
6. Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis. Lancet 1990;336:1582-3.
7. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet 1996;348:614.
8. Berman JD, Lee LS. Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg 1983;32:947-51.
9. Miltefosine. Frankfurt, Germany: ASTA Medica AG, January 1995 (brochure).
10. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6.
11. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992;36:1630-4.
12. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
13. Chulay JD, Bryceson ADM. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.
14. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis 1986;154:1003-11.
15. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996;124:664-72.
16. Hashim FA, Ali MS, Satti M, et al. An outbreak of acute kala-azar in a nomadic tribe in western Sudan: features of the disease in a previously non-immune population. Trans R Soc Trop Med Hyg 1994;88:431-2.
17. Hart D, Lux H, Parker P, Klenner T. Ether lipid (alkylphospholipid) analogs as antileishmanial drugs. Drugs Today 1998;34:Suppl F:117-31.
18. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344:1599-600.
19. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
20. Sundar S, Sinha PR, Agrawal NK, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998;59:139-43.
21. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ 1994;72:931-6.
22. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999;93:589-97.